Company Overview
Candel Therapeutics, Inc. operates as a clinical stage biopharmaceutical company dedicated to developing immunotherapies specifically designed for cancer patients. The company's primary focus is on advancing CAN-2409, which is currently undergoing Phase 2a clinical trials for the treatment of prostate cancer, alongside Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). This entity functions within the Healthcare sector and the Biotechnology industry, positioning itself in a high-risk, high-reward environment where capital is directed toward late-stage research and development rather than established commercial sales. With a market capitalization of $365.50M, a reported net income of $-38,182,000, and an employee count of 55, the company represents a micro-cap biotech firm with a lean operational structure. The market cap figure indicates that the company is valued significantly higher than its current book value, a common characteristic for biotechnology firms where future potential from pipeline assets drives valuation despite the absence of substantial current revenue streams.
Financial Health
The company reports net income (TTM) of $-38,182,000 and EBITDA of $-47,331,000, while revenue (TTM) and price-to-sales metrics are listed as N/A, reflecting the typical pre-revenue or early-stage commercialization profile of a clinical biopharmaceutical entity. The absence of reported revenue combined with significant net losses reveals a cost structure dominated by research and development expenditures and clinical trial costs rather than commercial overhead. Free cash flow stands at $-46,023,376, indicating that the company is consuming cash to fund its operations and development programs, which limits immediate financial flexibility but is standard for companies in the clinical stage. All three margins—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a figure that aligns with the N/A revenue status and underscores that the company has not yet generated profitable commercial sales to cover its substantial operating expenses. On the balance sheet, the company holds $119.73M in cash against $49.03M in debt, resulting in a debt-to-equity ratio of 94.44, which suggests a leveraged position relative to equity but provides a substantial cash buffer for ongoing development. The current ratio is 13.49, a metric that indicates exceptional short-term liquidity, suggesting the company has more than thirteen times the current assets required to cover its current liabilities without immediate distress. Return on Equity is -64.6% and Return on Assets is -25.9%, metrics that reveal management is currently deploying capital at a loss, a typical reality for biotech firms burning through cash reserves to reach commercial milestones.
Valuation Assessment
The valuation metrics present a unique picture for a company with no positive earnings, as the P/E Ratio (TTM) is N/A and the Forward P/E is -7.80. The negative forward P/E implies that analysts are projecting continued losses or earnings that do not yet reflect the current stock price, often seen in companies with large cash balances that are not generating income. The price-to-book ratio stands at 5.27, indicating that the market values the company at a significant premium over its net asset value, likely driven by the potential intrinsic value of the clinical pipeline rather than tangible assets. Alternative valuation metrics such as the Price-to-Sales ratio, which is N/A, and the EV/EBITDA of -6.23 further highlight that traditional multiples are not applicable for assessing this company's value in a standard manufacturing context. The stock has traded between a 52-week low of $4.25 and a 52-week high of $8.69, meaning the current valuation sits within a range that reflects significant volatility relative to the company's historical trading band. The beta of -0.90 is an anomaly that suggests the stock price moves inversely to the broader market, offering a hedge-like characteristic or reflecting specific sector-specific headwinds that decouple its performance from general market indices.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which is expected for a company that has not yet achieved commercial product launch or sustained positive earnings growth. Because the revenue and earnings figures are not positive, the concept of earnings growing faster than revenue is not applicable, as the company is currently in a phase of capital accumulation for clinical advancement rather than scaling sales. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning all available cash flow is retained and reinvested into the research and development of CAN-2409 and its clinical trials. The overall growth and income profile is characterized by a focus on long-term asset development and clinical trial progress rather than short-term income generation or dividend distributions to shareholders.